MediWound was founded as a biopharmaceutical enterprise focused on pioneering innovative enzymatic therapeutics derived from plant-based proteolytic enzymes to treat severe burns and chronic wounds. Over decades of clinical research and regulatory navigation, the company successfully commercialized NexoBrid across international pharmaceutical markets, established strategic manufacturing facilities, and advanced its pipeline assets—such as EscharEx—through late-stage clinical trials while executing public market listings.